Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects

Advances in the treatment of hematologic malignancies, allogeneic hematopoietic cell transplantation (HCT), and supportive care continue to improve post-HCT outcomes, and the number of long-term HCT survivors in the past decade has dramatically increased [1,2]. With improved post-HCT survival, it is increasingly important to consider late-treatment effects from chemotherapy and/or radiation and chronic graft-versus-host disease (GVHD) which may lead to decrements in quality of life and survival [3-5], especially since life expectancy post-HCT remains lower than that of the general population [2].

Source: Biology of Blood and Marrow Transplantation - April 27, 2024 Category: Hematology Authors: Richard A. Newcomb, Lucy Gao, Julie Vanderklish, Alexandra Tse, Meredith Saylor, Colleen Danielson, Nisha Wali, Matthew Frigault, Steven McAfee, Thomas Spitzer, Zachariah DeFilipp, Yi-Bin Chen, Hermioni L. Amonoo, Areej El-Jawahri Tags: Survivorship Source Type: research